Accessed May 24,2012 Liddle RA
GLP-3, as a triple agonist targeting GLP-1, GIP, and GCG receptors, holds significant promise as a research compound in the investigation of type 2 diabetesnot only through its observed influence on glycemic parameters but also via its substantial impact on weight reduction
Safety Position : Neither Eli Lilly nor independent investigators have endorsed higher doses
Before starting, stopping, or asking about any prescription medication, including any drug in the GLP-1 or triple-agonist class, talk to a licensed physician who knows your medical history
If you're currently on a GLP-1 medication or preparing for one, the same high-protein, portion-controlled eating strategies apply
That growing interest pushes prices even higher